Nerve surgery or eye drops for neurotrophic keratitis
Part of Eyes & vision clinical trials.
This study compares two treatments for neurotrophic keratitis, a condition where the cornea (the clear front part of the eye) loses feeling due to nerve damage. One treatment is a surgery that restores nerves to the cornea, and the other is a special eye drop that helps the cornea heal. The goal is to see which treatment works better for improving eye health and vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years of age or older.
- You have been diagnosed with neurotrophic keratitis (a condition where the cornea has reduced or no feeling).
- Your eye doctor has determined that you need either nerve surgery or the eye drop treatment.
- You are able to give informed consent to participate.
- You do not have an active eye infection or inflammation.
- You have not had this type of nerve surgery in the affected eye before.
- You are not participating in another clinical trial within the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental eye drop (STSP-0902) for a condition called neurotrophic keratitis, where the cornea (the clear front part of the eye) gets scratches or sores because nerves are damaged. The drop contains a growth factor to help the eye heal. You might be eligible if you have a persistent scratch or sore on your cornea that has not improved for at least a week.
This trial tests whether a new eye drop called Lacripep can help treat neurotrophic keratitis, a rare eye condition where the cornea loses sensation and can become damaged. The study compares Lacripep to a placebo (inactive) drop to see if it improves corneal healing and vision.
This Phase 2 trial tests BRM424 eye drops in adults with neurotrophic keratitis (a weakened, slow-healing cornea) to see if they help and are safe over 28 days. You may be able to join if your condition matches Stage 2 or Stage 3 and you meet the safety rules.
This trial tests whether KB801 can help heal persistent corneal defects better than a placebo. It is for people with neurotrophic keratitis (a condition where the cornea loses sensation) that has not improved with standard care.
This Phase 3 trial tests whether a 0.1% RGN-259 eye drop can safely improve a stubborn corneal wound in adults with neurotrophic keratopathy (nerve-related corneal healing problems). You may qualify if you still have an eye surface defect after at least a week of standard treatments, and you meet specific measurements for corneal sensitivity and vision.
This trial tests a new eye drop (acoltrepon) to see if it helps people with stage 1 neurotrophic keratopathy (a condition where the cornea's nerves are damaged, causing dry eyes and vision problems) and low tear production. It aims to improve signs like corneal staining and symptoms of discomfort.
Hear when a new Neurotrophic Keratitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.